Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Costs Of Treating Dystonias And Hemifacial Spasm With Botulinum Toxin A

R. Dodel, A. Kirchner, R. Koehne-Volland, G. Künig, A. Ceballos-Baumann, M. Naumann, A. Brashear, H. Richter, T. Szucs, W. Oertel
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
SummaryBotulinum toxin (BTX) has become a safe and effective therapeutic tool in the treatment of a variety of neurological disorders, especially dystonias. One major disadvantage, however, is the high cost of a single injection of BTX. In this study of 835 patients, we calculated the cost of treatment with BTX serotype A (BTX-A) for different dystonias and hemifacial spasm.The annual expenditure per patient for BTX-A injections in this cohort totalled (mean ± standard deviation) 1030 Deutschmarks (DM) 1996 values ±DM610 [$US570 ± $US340; 230 ± 130 pounds sterling (£)] for blepharospasm (n = 158), DM1450 ±DM1520 ($US800 ± $US830; £310 ±£280) for craniocervical dystonia (n = 148), and DM1480 ± DM780 ($US810 ± $US430; £330 ± £180) for oromandibular dystonia (n = 16), while the treatment of cervical dystonia consumed DM4590 ±DM2060 ($US2520 ± $US1130; £960 ± £420) [n = 362] per patient. In order to alleviate symptoms in patients with hemifacial spasm (n = 151), DM51 0 ± DM270 ($US280 ± $US150; £110 ± £60) had to be spent annually. The expenses for surgical therapy for cervical dystonia were DM10 120 ± DM1900 (n= 54). No major differences concerning expenditure could be found in this study between the 2 available preparations of BTX. However, there appeared to be a lower rate of adverse effects with the Botox® formulation, compared with the Dysport® formulation, of BTX- (this difference was statistically significant i.e. p<0.001)Although the cost of an individual injection is high, other cost factors also substantially contribute to the societal costs of adult-onset dystonias. Some of these costs may be attenuated with the use of BTX. The subjective and objective relief of these socially devastating and sometimes painful conditions rewards the expenditure associated with the use of BTX-A
This paper references
10.1212/WNL.41.8.1185
Botulinum toxin treatment of tremors
J. Jankovic (1991)
Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation.
T. Odergren (1994)
10.1212/WNL.45.11.2109
Botulinum toxin type B in the treatment of cervical dystonia
Joseph King Ching Tsui (1995)
10.1212/WNL.35.1.73
Validity and reliability of a rating scale for the primary torsion dystonias
R. Burke (1985)
Geblihrenordnung flir Arzte, GOA, BGGOA
R. Mundenbruch (1994)
10.1212/wnl.44.12.2401
Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders
R. Anderson (1994)
Cost utility analysis of botulinum toxin therapy in the treatment of dystonia [ abstract ]
F Bochner (1994)
Craniocervical dystonias: descriptive category or nosological entity
B Csala (1994)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
10.1016/S0733-8619(18)30311-6
Botulinum toxin therapy.
P. Savino (1991)
10.1002/MDS.870110327
Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan.
Louis Ed (1996)
10.1212/WNL.45.3.506
Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm
T. Mezaki (1995)
Structure of botulinum neurotoxin , its functional domains , and perspectives on the crystalline type A toxin
BR DasGupta
10.1136/jnnp.49.6.651
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm.
P. Thompson (1986)
10.1001/ARCHNEUR.1990.00530110095023
Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984.
R. Auger (1990)
10.1002/MDS.870080323
Significant improvement of stiff‐person syndrome after paraspinal injection of botulinum toxin A
D. Davis (1993)
10.1212/WNL.41.7.1088
Cervical dystonia
J. Jankovic (1991)
10.1097/00019052-199408000-00014
Botulinum toxin in movement disorders
J. Jankovic (1994)
10.1111/J.1365-2125.1981.TB01118.X
Assessment of extrapyramidal disorders.
C. Marsden (1981)
10.1001/ARCHNEUR.1990.00530050070014
Natural history of adult-onset idiopathic torticollis.
M. Jahanshahi (1990)
10.1001/ARCHNEUR.1991.00530240057020
Clinical correlates of response to botulinum toxin injections.
J. Jankovic (1991)
10.1136/jnnp.60.2.204
Sex prevalence of focal dystonias.
V. Soland (1996)
10.1097/00002341-199603000-00019
Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study
M. Keen (1996)
10.1212/WNL.42.4.878
Botulinum toxin injection for spasmodic torticollis
C. Comella (1992)
10.1212/WNL.35.3.423
“Apraxia” of eyelid opening
F. E. Lepore (1985)
10.1002/MDS.870100513
Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota
D. W. Claypool (1995)
Therapeutische An - wendung von Botulinum A Toxin in der Neurologie
A Albanese (1994)
10.1016/0967-5868(95)90015-2
Movement disorders 3: Marsden C D, Fahn S Butterworth-Heinemann UK, 1994 ISBN 0 750614 12 9 529pp RRP $110.00
D. Serisier (1995)
10.1055/S-2008-1063650
Behandlung des Torticollis spasmodicus mit lokalen Injektionen von Botulinustoxin A
F. Erbguth (2008)
10.1007/BF00181883
Botulinum toxin treatment in patients with hemifacial spasm
R. Laskawi (2004)
10.1017/S0317167100023830
Pathophysiology and pharmacotherapy of spasmodic torticollis: a review.
S. Lal (1979)
10.1001/ARCHOTOL.1988.01860240057024
Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)
A. W. Biglan (1988)
10.1002/MDS.870100619
Cervical dystonia and botulinum treatment: Is electromyographic guidance necessary?
J. Speelman (1995)
10.1136/jnnp.53.8.640
Botulinum toxin treatment in spasmodic torticollis.
J. Blackie (1990)
10.1016/0022-510X(71)90129-8
An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse.
L. Duchen (1971)
10.1227/00006123-199407000-00009
Selective peripheral denervation for the treatment of spasmodic torticollis.
V. Braun (1994)
10.1128/MMBR.56.1.80-99.1992
Properties and use of botulinum toxin and other microbial neurotoxins in medicine.
E. Schantz (1992)
10.2105/AJPH.70.12.1249
The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis.
N. S. Hartunian (1980)
10.3109/9780203450321-49
Therapy with botulinum toxin
J. Jankovic (1994)
[Craniocervical dystonia. Pragmatic general concept or nosologic entity?].
B. Csala (1994)
10.1056/NEJM199201303260516
Therapeutic use of type F botulinum toxin.
C. Ludlow (1992)
10.1016/B978-0-444-52014-2.00048-3
Hemifacial spasm.
G. Abbruzzese (2011)
10.1002/mds.870070530
Drug induced movement disorders
J. M. Velázquez-Pérez (2009)
Five-year experience in the treatment of focal movement disorders with lowdose Dysport® botulinum toxin. Muscle Nerve
P Van den Bergh (1995)
10.1212/WNL.48.1.249
Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use
R. Sloop (1997)
Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan.
E. Louis (1996)
10.1002/MDS.870030302
Epidemiology of focal and generalized dystonia in Rochester, Minnesota
J. Nutt (1988)
10.1136/bmj.300.6718.139
The dystonias.
C. Marsden (1990)
Lokale injektionsbehandlung mit Botulinumtoxin A bei Blepharos - pasmus , Meige - syndrom und Spasmus hemifacial is
AO Ceballos-Baumann (1990)
10.1177/000348949110000201
Laryngeal Dystonia: A Series with Botulinum Toxin Therapy
A. Blitzer (1991)
10.1038/eye.1988.6
Botulinum toxin therapy for squint
J. Lee (1988)
10.1192/PB.18.5.304
British National Formulary
A. B. Prasad (1994)
10.1007/BF00867420
Selective peripheral denervation for spasmodic torticollis: is the outcome predictable?
V. Braun (2004)
10.1212/WNL.36.3.398
Spontaneous remissions in spasmodic torticollis
A. Friedman (1986)
Botulinum toxin: dangerous terminology errors.
M. Brin (1993)
eta!. Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study
L Erhardt (1997)
10.1007/978-1-4684-5038-5_19
Drug-Induced Movement Disorders
Stewart A. Factor (1992)
Medico-legal reports.
McCormack Mp (1993)
Acute anticholinergic action in focal dystonia.
A. Lang (1983)
10.1002/MUS.880180708
Five‐year experience in the treatment of focal movement disorders with low‐dose dysportTM botulinum toxin
P. V. D. van den Bergh (1995)
10.1212/WNL.39.10.1404
Botulinum toxin in torticollis
D. Gelb (1989)
10.1097/00006534-199407000-00009
Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study
M. Keen (1994)
10.1159/000100734
Observations and analysis of results in 131 cases of spasmodic torticollis after selective denervation.
C. Bertrand (1987)
10.1212/WNL.43.4.834
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia
J. Jankovic (1993)
10.1111/j.1365-2036.1995.tb00428.x
Review article The use of botulinum toxin in the alimentary tract
Alberto Albanese (1995)
Classification and investigation of dystonia
CD Marsden (1987)
10.1016/0022-5193(79)90141-3
Toxicity of botulinum toxin: a stoichiometric model for the locus of its extraordinary potency and persistence at the neuromuscular junction.
J. Hanig (1979)
10.1212/WNL.45.4.712
Botulinum toxin A for spasticity, muscle spasms, and rigidity
M. Grazko (1995)
10.1111/j.1365-2958.1994.tb00396.x
Mechanism of action of tetanus and botulinum neurotoxins
C. Montecucco (1994)
10.3928/0191-3913-19800101-06
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
A. B. Scott (1980)
10.1136/BMJ.308.6933.901
How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. Drug Committee of the Royal Adelaide Hospital.
F. Bochner (1994)
10.1002/ARDP.19632960715
Rote Liste 1963, Verzeichnis pharmazeutischer Spezialpräparate der Mitglieder des Bundesverbandes der Pharmazeutischen Industrie e. V., Herausgeber: Bundesverband der pharmazeutischen Industrie e. V., Frankfurt/M. Editio Cantor, Aulendorf/Württ. 1963. V, 1296 Seiten. Preis DM 20,—
Knabe (1963)
10.1136/jnnp.55.3.229
Psychological functioning before and after treatment of torticollis with botulinum toxin.
M. Jahanshahi (1992)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar